A5027058055- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Viral-associated cancers and disorders
- Cancer Treatment and Pharmacology
- Neutropenia and Cancer Infections
- CNS Lymphoma Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Immunodeficiency and Autoimmune Disorders
- Histone Deacetylase Inhibitors Research
- Hematopoietic Stem Cell Transplantation
- Hematological disorders and diagnostics
- Lung Cancer Treatments and Mutations
- Blood disorders and treatments
- Peptidase Inhibition and Analysis
- Iron Metabolism and Disorders
- Pharmacological Effects and Toxicity Studies
- Immune Cell Function and Interaction
- Pneumocystis jirovecii pneumonia detection and treatment
- Trace Elements in Health
Medisch Centrum Leeuwarden
2016-2025
University of Padua
2019
Institute of Molecular Medicine
2019
Hudson Institute
2018
John Wiley & Sons (United States)
2018
Medisch Spectrum Twente
2017
Erasmus MC
2017
Janssen (Belgium)
2017
Friesland College
2017
Leiden University Medical Center
2004-2007
Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden coexisting conditions) advanced chronic lymphocytic leukemia (CLL) have been lacking. Download PDF the Research Summary. In phase 3, open-label trial, we randomly assigned, 1:1:1:1 ratio, CLL who did not TP53 aberrations to receive six cycles chemoimmunotherapy (fludarabine–cyclophosphamide–rituximab or bendamustine–rituximab) 12 venetoclax–rituximab,...
Abstract Morbidity and mortality due to immunosuppression remain among the foremost clinical challenges in chronic lymphocytic leukemia (CLL). Although is considered originate within lymph node (LN) microenvironment, alterations T natural killer (NK) cells have almost exclusively been studied peripheral blood (PB). Whereas chemoimmunotherapy further deteriorates immune function, novel targeted agents like B-cell lymphoma 2 inhibitor venetoclax potentially spare nonmalignant lymphocytes;...
ABSTRACT Approximately 40%–60% of patients reaching a stable deep molecular response during TKI treatment will maintain state remission after discontinuation, denoted as treatment‐free (TFR). Depth assessed by BCR::ABL1 digital PCR prior to discontinuation has demonstrated its significance reliable predictive parameter for TFR. A clinically applicable prediction cutoff 0.0023%IS been established and externally validated. In this study, PCR, most sensitive assay kind, was investigated TFR...
Summary The efficacy of azacitidine in the treatment high‐risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid (AML) (20–30% blasts) has been demonstrated. To investigate daily clinical practice to identify predictors for response, we analysed a cohort 90 MDS, CMML AML patients who have treated Dutch compassionate named patient programme. Patients received median five cycles (range 1–19). overall response rate (complete/partial/haematological...
An observational population-based cohort study was performed to investigate the role of comorbidity on outcome and treatment-related toxicity in patients with newly diagnosed advanced-stage diffuse large B-cell lymphoma (DLBCL) treated R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Data for clinical characteristics 154 (median age 69 years), including Charlson Comorbidity Index (CCI), treatment, were evaluated. Forty-five percent had an International Prognistic...
Plasmacytoma is characterized by a local accumulation of monoclonal plasma cells without criteria for multiple myeloma ( MM ). The current treatment regimen radiotherapy. However, more than 50% patients develop within 2 years after treatment. A population‐based registry was consulted the diagnosis solitary plasmacytoma between 1988 and 2011. Progression to prognostic features progression were scored, including hypoxia inducible factors HIF ), vascular endothelial growth factor VEGF , also...
Immunochemotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become standard of care for patients diffuse large B-cell lymphoma (DLBCL). This randomized trial assessed whether intensification during the first 4 cycles R-CHOP could improve outcome these compared R-CHOP.A total 574 DLBCL age 18 to 80 years were randomly assigned induction therapy 6 or 8 R-CHOP-14 (RR-CHOP-14) without (R-CHOP-14) in cycles. The primary end point was complete...
Abstract Lenalidomide, an antineoplastic and immunomodulatory drug, has therapeutic activity in acute myeloid leukemia (AML), but definitive studies about its utility have been lacking. In a phase 3 study, we compared 2 induction regimens newly diagnosed patients age 18 to 65 years with AML: idarubicine-cytarabine (cycle 1) daunorubicin intermediate-dose cytarabine 2) without or lenalidomide (15 mg orally on days 1-21). One final consolidation cycle of chemotherapy autologous stem cell...
Evaluations of the 'real-world' efficacy and safety tyrosine kinase inhibitors in patients with chronic myeloid leukemia are scarce. A nationwide, population-based, registry was analyzed to evaluate (deep) response rates first subsequent treatment lines eligibility for a cessation attempt adults diagnosed between January 2008 April 2013 Netherlands. The covered 457 patients; 434 phase (95%) 15 (3%) advanced disease phase. Seventy-five percent were treated imatinib 25% second-generation...
To assess treatment strategies, toxicity and outcome in very elderly patients (aged ≥ 75 years) diagnosed with diffuse large B-cell lymphoma (DLBCL) the rituximab era, an observational population-based cohort study was performed. From 103 a median age of 81 years, data clinical characteristics, treatment, were evaluated. Advanced stage DLBCL documented 74 patients. In 80 chemotherapy initiated; 70 received rituximab, cyclophosphamide, doxorubicin, vincristine prednisolone (R-CHOP). this...
The efficacy of azacitidine has been demonstrated in acute myeloid leukemia (AML) patients with 20-30% bone marrow (BM) blasts, but limited data is available on ≥30% blasts. We analyzed 55 newly diagnosed AML patients, treated azacitidine. overall response rate was 42%. Median survival (OS) 12.3 months. confirmed poor-risk cytogenetics, therapy-related AML, performance score ≥2, and white blood cell count ≥15×10(9)/L as independent adverse predictors for OS. BM blast percentage, however, had...
This case illustrates the potential for systemic cobalt toxicity in non-metal-on-metal bearings and its potentially devastating consequences. We present a 71-year-old male with grinding sensations his right hip following ceramic-on-ceramic total arthroplasty (THA). After diagnosing fractured ceramic liner, prosthesis was revised into metal-on-polyethylene bearing. At one year postoperatively, X-rays MARS-MRI showed fixed reversed hybrid THA, periarticular densities, flattening of femoral...
The detection of minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) may improve future risk-adapted treatment strategies. We assessed whether MRD-positive and MRD-negative AML benefit differently from the graft-versus-leukemia effect allogeneic hematopoietic stem-cell transplantation (alloHSCT).A total 1,511 were treated subsequent Dutch-Belgian Hemato-Oncology Cooperative Group Swiss for Clinical Cancer Research trials, whom 547 obtained a first complete remission,...
The treatment of older, unfit patients with acute myeloid leukemia (AML) is challenging. Based on preclinical data Bruton tyrosine kinase expression/phosphorylation and ibrutinib cytotoxicity in AML blasts, we conducted a randomized phase 2 multicenter study to assess the tolerability efficacy addition 10-day decitabine (ie, Hematopoietic Cell Transplantation Comorbidity Index ≥3) higher risk myelodysplasia (HOVON135/SAKK30/15 trial). In total, 144 eligible were randomly (1:1) assigned...
Acute myeloid leukemia (AML) is a malignancy of the bone marrow with median age at diagnosis 70 years. AML difficult to treat, especially in older patients, among whom outcomes have historically been poor. Over last two decades, greater understanding molecular mechanisms pathology has led development new drugs and multiple updates treatment guidelines.